Related Experiment Video
Updated: Mar 29, 2026
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Diagnostic Value of Circulating CXC Chemokines in Non-small Cell Lung Cancer
Artjoms Spaks1, Inta Jaunalksne2, Irina Spaka3
1Department of Thoracic Surgery, Harefield Hospital, The Royal Brompton and Harefield Hospital NHS Foundation Trust, Harefield, Middlesex, U.K. Department of Thoracic Surgery, Pauls Stradins Clinical University Hospital, Riga, Latvia artjoms.spaks@stradini.lv.
Background/Aim:
To evaluate the diagnostic value of circulating CXC chemokines as biomarkers for non-small cell lung cancer and compare them against a standard panel of already existing cancer biomarkers.
Materials And Methods:
A total of 90 individuals were enrolled in the study. We analyzed 30 patients with stage IA-IIB carcinoma of the lung who underwent pulmonary resection, 30 patients with metastatic NSCLC, and 30 healthy volunteers. The biomarkers levels were measured in plasma blood samples, by ELISA and immunoassays.
Results:
The levels of circulating CXCL4, CXCL8, CXCL9, CXCL10 and CXCL11 were higher and those of circulating CXCL1 were lower in patients with early-stage NSCLC compared to metastatic NSCLC patients and controls (p<0.05). CXCL4, CXCL9 and CXCL11 were included in the panel that showed a sensitivity of 100% versus 60% for CEA, CA125 and CYFRA21-1 (p<0.001).
Conclusion:
Combination of CXCL4, CXCL9 and CXCL11 has a high diagnostic value.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
05:17Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
Published on: May 14, 2019